Several positive headlines for various drug companies combined to push the biotech sector higher and bring the other indices along with it. Keith Bliss of Cuttone points out the biotech sector had been oversold, but with good news buyers came to the table. Amgen's cholesterol drug sees positive results and Biogen receives approval from the FDA on a hemophilia drug, while Curis has positive developments on its cancer drug and Novartis sees success with its heart failure drug.
More from Video
AMSC CEO discusses that and China challenges.
One of pharma's biggest CEO's talks M&A action on the exchange.
Citi overcame a mixed print to send its stock surging on Monday.
There is a lot of Apple news to chew on Wednesday.